Blood pressure lowering in patients with diabetes-one level might not fit all

Nature Reviews Cardiology

Volumn 8, Issue 1, 2011, Pages 42-49

  Cooper Dehoff, Rhonda M ^a   Egelund, Eric F ^a   Pepine, Carl J ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; PERINDOPRIL; PLACEBO; TRANDOLAPRIL PLUS VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; MICROALBUMINURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; DRUG EFFECT; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78651485079     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.182     Document Type: Review

References (66)

1. Stamler, J., Vaccaro, O., Neaton, J. D. & Wentworth, D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993).
2. Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37, 1053-1059 (2001).
3. [No authors listed] The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 144, 1045-1057 (1984).
4. [No authors listed] The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC v). Arch. Intern. Med. 153, 154-183 (1993).
5. [No authors listed] The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 157, 2413-2446 (1997).
6. Chobanian, A. V. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
7. Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28, 1462-1536 (2007).
8. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 25, 199-201 (2002).
9. Hansson, L. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351, 1755-1762 (1998). (Pubitemid 28269185)
10. [No authors listed] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317, 703-713 (1998).
11. Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
12. Cooper-DeHoff, R. M. et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304, 61-68 (2010).
13. International Diabetes Federation. About diabetes [online], http://www.idf.org/about-diabetes (2010).
14. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
15. Kannel, W. B., Wilson, P. W. & Zhang, T. J. The epidemiology of impaired glucose tolerance and hypertension. Am. Heart J. 121, 1268-1273 (1991).
16. Klein, R., Klein, B. E., Lee, K. E., Cruickshanks, K. J. & Moss, S. E. The incidence of hypertension in insulin-dependent diabetes. Arch. Intern. Med. 156, 622-627 (1996).
17. Fryar, C. D., Hirsch, R., Eberhardt, M. S., Yoon, S. S. & Wright, J. D. Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence differences in U. S. adults, 1999-2006 [online], http://www.cdc.gov/ nchs/data/databriefs/db36.pdf (2010).
18. Mancia, G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 42 (Suppl. 1), S17-S25 (2005).
19. Creager, M. A., Lüscher, T. F., Cosentino, F. & Beckman, J. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108, 1527-1532 (2003). (Pubitemid 37176462)
20. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörölä, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998).
21. Stern, M. P. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44, 369-374 (1995).
22. Redon, J. et al. Mechanisms of hypertension in the cardiometabolic syndrome. J. Hypertens. 27, 441-451 (2009).
23. Cooper, S. A. et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am. J. Physiol. Heart Circ. Physiol. 293, H2009-H2023 (2007).
24. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. & Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
25. Adler, A. I. et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321, 412-419 (2000).
26. Avins, A. L. When clinical practice guidelines meet the black box. Arch. Intern. Med. 170, 1013-1014 (2010).
27. [No authors listed] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355, 253-259 (2000).
28. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 25, 213-229 (2002).
29. American Diabetes Association. Standards of medical care in diabetes\2010. Diabetes Care 33 (Suppl. 1), S11-S61 (2010)
30. Chobanian, A. v. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
31. Cushman, W. C. et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am. J. Cardiol. 99, 44i-55i (2007).
32. Yusuf, S. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
33. Braunwald, E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
35. Curb, J. D. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276, 1886-1892 (1996).
36. Staessen, J. A. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350, 757-764 (1997).
37. Tuomilehto, J. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340, 677-684 (1999).
38. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADvANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
39. Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. & Matthews, D. R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359, 1565-1576 (2008).
40. Schrier, R. W., Estacio, R. O. & Jeffers, B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 39, 1646-1654 (1996).
41. Estacio, R. O. et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338, 645-652 (1998).
42. Schrier, R. W., Estacio, R. O., Esler, A. & Mehler, P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086-1097 (2002).
43. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
44. Berl, T. et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 16, 2170-2179 (2005).
45. Pepine, C. J. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International verapamil-Trandolapril Study (INvEST): a randomized controlled trial. JAMA 290, 2805-2816 (2003).
46. Chew, E. Y. et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233-244 (2010).
47. [No authors listed] The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 148, 1023-1038 (1988).
48. American Diabetes Association. Diabetic nephropathy. Diabetes Care 25 (Suppl. 1), S85-S88 (2002).
49. Mancia, G. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009).
50. Turnbull, F. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165, 1410-1419 (2005).
51. Mancia, G. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25, 1751-1762 (2007).
52. Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
53. Weber, M. A. et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56, 77-85 (2010).
54. Cruickshank, J. M., Thorp, J. M. & Zacharias, F. J. Benefits and potential harm of lowering high blood pressure. Lancet 1, 581-584 (1987).
55. Alderman, M. H., Ooi, W. L., Madhavan, S. & Cohen, H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA 262, 920-924 (1989).
56. Farnett, L., Mulrow, C. D., Linn, W. D., Lucey, C. R. & Tuley, M. R. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 265, 489-495 (1991).
57. Grossman, E. Does the 'J-curve' still hold in the post 'HOT' era? J. Hum. Hypertens. 12, 729-730 (1998).
58. Ibsen, H. Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension. J. Hum. Hypertens. 12, 731-732 (1998).
59. Messerli, F. H. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med. 144, 884-893 (2006).
60. Bakris, G. L. et al. Clinical outcomes in the diabetes cohort of the International verapamil SR-Trandolapril study. Hypertension 44, 637-642 (2004).
61. Rönnback, M. et al. Complex relationship between blood pressure and mortality in type 2 diabetic patients: a follow-up of the Botnia Study. Hypertension 47, 168-173 (2006).
62. Van Hateren, K. J. et al. Lower blood pressure associated with higher mortality in elderly diabetic patients (ZODIAC-12). Age Ageing 39, 603-609 (2010).
63. Timbie, J. W., Hayward, R. A. & vijan, S. variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch. Intern. Med. 170, 1037-1044 (2010).
64. Hansson, L. & Zanchetti, A. The Hypertension Optimal Treatment (HOT) Study\patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press. 3, 322-327 (1994).
65. Ginsberg, H. N. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
66. Boyle, J. P. et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24, 1936-1940 (2001).